Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response

Publication | Closed Access

DOI

Citations

References

2006

Year

Achim Rody, Thomas Karn, R. Gätje, A. Ahr, Christine Solbach, K. Kourtis, Marc Munnes, Sibylle Loibl, Stefan Kissler, Eugen Ruckhäberle,

The Breast

Tumor ResponseBreast OncologyBreast Cancer PatientsMedicinePathologyCancer GenomicsBreast CancerCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentTumor BiologyEndocrine-related CancerGene Expression Profiling